Safety and Outcomes of Ventricular Tachycardia Substrate Ablation During Sinus Rhythm: A Prospective Multicenter Registry.


Journal

JACC. Clinical electrophysiology
ISSN: 2405-5018
Titre abrégé: JACC Clin Electrophysiol
Pays: United States
ID NLM: 101656995

Informations de publication

Date de publication:
26 10 2020
Historique:
received: 05 06 2020
revised: 16 07 2020
accepted: 29 07 2020
entrez: 30 10 2020
pubmed: 31 10 2020
medline: 19 8 2021
Statut: ppublish

Résumé

This study sought to analyze safety and outcomes of ventricular tachycardia (VT) substrate ablation during sinus rhythm (SR), without baseline VT induction. Safety and outcomes after scar-related VT ablation during SR are not well known. Hemodynamic instability and need for electrical cardioversion can compromise safety of VT ablation procedures. Four hundred twelve consecutive patients with structural heart disease undergoing VT ablation were included in a prospective multicenter registry. Substrate ablation during SR, without baseline VT induction, was the first step of the ablation procedure and the standard protocol. Scar dechanneling was the substrate ablation technique used. VT inducibility was tested after substrate ablation. VT induction protocol was negative after substrate ablation in 289 patients (70.1%), completing the procedure in SR. Procedure-related complication rate was 6.5%, including 1 death (0.2%). Thirty-day mortality after first VT ablation procedure was 1.7%. Overall survival was 95.8% and 88.6% at 1 and 3 years of follow-up, respectively. In a multivariable proportional hazards regression model, age ≥70 years (hazard ratio [HR]: 4.95 [2.59 to 9.47]; p < 0.001), chronic obstructive pulmonary disease (HR: 2.37 [1.24 to 4.52]; p = 0.008), left ventricular ejection fraction <30% (HR: 2.43 [1.37 to 4.33]; p = 0.002), and incomplete substrate ablation (HR: 2.37 [1.24 to 4.52]; p = 0.026) were independent predictors of overall mortality. At 12 months' follow-up, VT-free survival was 82.5% after 1 procedure and 87.8% after n procedures CONCLUSIONS: Substrate ablation during SR avoiding multiple VT induction has low procedure-related complications and low early mortality. Age, chronic obstructive pulmonary disease, and reduced left ventricular ejection fraction, but also incomplete substrate elimination, are predictors of mortality.

Sections du résumé

OBJECTIVES
This study sought to analyze safety and outcomes of ventricular tachycardia (VT) substrate ablation during sinus rhythm (SR), without baseline VT induction.
BACKGROUND
Safety and outcomes after scar-related VT ablation during SR are not well known. Hemodynamic instability and need for electrical cardioversion can compromise safety of VT ablation procedures.
METHODS
Four hundred twelve consecutive patients with structural heart disease undergoing VT ablation were included in a prospective multicenter registry. Substrate ablation during SR, without baseline VT induction, was the first step of the ablation procedure and the standard protocol. Scar dechanneling was the substrate ablation technique used. VT inducibility was tested after substrate ablation.
RESULTS
VT induction protocol was negative after substrate ablation in 289 patients (70.1%), completing the procedure in SR. Procedure-related complication rate was 6.5%, including 1 death (0.2%). Thirty-day mortality after first VT ablation procedure was 1.7%. Overall survival was 95.8% and 88.6% at 1 and 3 years of follow-up, respectively. In a multivariable proportional hazards regression model, age ≥70 years (hazard ratio [HR]: 4.95 [2.59 to 9.47]; p < 0.001), chronic obstructive pulmonary disease (HR: 2.37 [1.24 to 4.52]; p = 0.008), left ventricular ejection fraction <30% (HR: 2.43 [1.37 to 4.33]; p = 0.002), and incomplete substrate ablation (HR: 2.37 [1.24 to 4.52]; p = 0.026) were independent predictors of overall mortality. At 12 months' follow-up, VT-free survival was 82.5% after 1 procedure and 87.8% after n procedures CONCLUSIONS: Substrate ablation during SR avoiding multiple VT induction has low procedure-related complications and low early mortality. Age, chronic obstructive pulmonary disease, and reduced left ventricular ejection fraction, but also incomplete substrate elimination, are predictors of mortality.

Identifiants

pubmed: 33121673
pii: S2405-500X(20)30714-3
doi: 10.1016/j.jacep.2020.07.028
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

1435-1448

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2020 The Authors. Published by Elsevier Inc. All rights reserved.

Auteurs

Juan Fernandez-Armenta (J)

Department of Cardiology, Puerta del Mar University Hospital, Cadiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, Spain.

David Soto-Iglesias (D)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Heart Institute, Teknon Medical Center, Barcelona, Spain.

Etel Silva (E)

Department of Cardiology, Puerta del Mar University Hospital, Cadiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, Spain.

Diego Penela (D)

Heart Institute, Teknon Medical Center, Barcelona, Spain; Department of Cardiology, Guglielmo da Saliceto Hospital, Piacenza, Italy.

Beatriz Jáuregui (B)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Heart Institute, Teknon Medical Center, Barcelona, Spain.

Markus Linhart (M)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

Felipe Bisbal (F)

Institut del Cor (iCor), Germans Trias i Pujol University Hospital, Badalona, Spain.

Juan Acosta (J)

Department of Cardiology, Virgen del Rocio University Hospital, Seville, Spain.

Marcos Fernandez (M)

Department of Cardiology, Puerta del Mar University Hospital, Cadiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, Spain.

Roger Borras (R)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

Roger Villuendas (R)

Institut del Cor (iCor), Germans Trias i Pujol University Hospital, Badalona, Spain.

Lucas Cano (L)

Department of Cardiology, Puerta del Mar University Hospital, Cadiz, Spain; Biomedical Research and Innovation Institute of Cadiz (INiBICA), Cadiz, Spain.

Eduard Guasch (E)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

Lluis Mont (L)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain.

Antonio Berruezo (A)

Arrhythmia Unit, Department of Cardiology, Cardiovascular Clinical Institute, Hospital Clinic, Universitat de Barcelona, Barcelona, Spain; Heart Institute, Teknon Medical Center, Barcelona, Spain. Electronic address: antonio.berruezo@quironsalud.es.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH